Teladoc Health, Inc.

Teladoc Health, Inc. announced that Mr. David B. Snow, Jr. will retire from its Board of Directors, effective September 30, 2026. Mr. Snow, who has been a director since 2014, cited personal reasons for his departure. The company confirmed that his retirement is not due to any disagreement with Teladoc Health.

Teladoc Health announced the appointment of Mark V. Anquillare to its board of directors. Mr. Anquillare, former president and chief operating officer of Verisk Analytics, brings over 30 years of financial and executive leadership experience, including guiding Verisk through its IPO. He will serve on the board’s Audit & Compensation committees, with his expertise in data, technology, and AI expected to be invaluable for Teladoc Health's growth.

Teladoc Health reported mixed financial results for Q2 2026, with revenue decreasing 4% year-over-year to $606.9 million and a net loss of $38.9 million. Adjusted EBITDA also saw a 5% decline to $65.7 million. The Integrated Care segment showed growth with revenue up 1% and a healthy adjusted EBITDA margin, while the BetterHelp segment experienced a significant 12% revenue decline due to accelerated pressure on cash pay revenue. The company provided a full-year 2026 revenue outlook of $2,362 million to $2,447 million and adjusted EBITDA of $271 million to $303 million, reflecting ongoing challenges in BetterHelp but strategic actions to scale insurance offerings.

Teladoc Health announced the launch of Teladoc One, a new virtual care model designed to provide a single, adaptive experience to improve health outcomes and reduce healthcare costs. This model addresses fragmented care by offering multidisciplinary care teams, always-on AI support, and personalized care pathways. Teladoc Health is aligning its program economics by placing 100% of its fees at risk, linking payment directly to performance on clinical outcome measures and total cost of care improvement. Programs will roll out with select clients in September 2026, with broader availability starting January 2027.

Teladoc Health, Inc. announced it will release its second quarter 2026 financial results on Wednesday, July 29, 2026, after the market closes. Following the release, the company will host a conference call at 5:00 p.m. ET on the same day to discuss the results. Investors can access the call via dial-in numbers or a live audio webcast, with a replay available for 90 days.

Teladoc Health, Inc. announced the appointment of David Packles as the new Head of Product for its BetterHelp subsidiary, effective July 1, 2026. In connection with his new role, Mr. Packles received an inducement award of 50,000 restricted stock units of Teladoc Health's common stock. The award, approved by the Compensation Committee, vests over approximately three years, with one-third vesting on the first anniversary and the remainder quarterly over the subsequent two years.

Teladoc Health, Inc. reported Q1 2026 financial results with revenue down 2% year-over-year to $613.8 million. The company's net loss improved by 31% to $63.8 million, or $0.36 per share, while adjusted EBITDA remained essentially flat at $58.2 million. Integrated Care segment revenue grew 2%, offsetting a 9% decline in the BetterHelp segment. Teladoc Health reaffirmed the midpoint of its full-year financial outlook for 2026.

Teladoc Health, Inc. announced it will release its first-quarter 2026 financial results on Wednesday, April 29, 2026, after the market closes. The company will host a conference call at 5:00 p.m. ET on the same day to discuss the results. Investors can access the call via dial-in or a live audio webcast, with a replay available for approximately 90 days.